<DOC>
	<DOCNO>NCT00384891</DOCNO>
	<brief_summary>The study design compare efficacy safety 2 treatment type prevention tumor recurrence superficial bladder cancer : 1 . A combination bladder wall heat local chemotherapy ( Synergo ) 2 . Bacillus Calmette-Guérin ( BCG )</brief_summary>
	<brief_title>Hyperthermia Treatment Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy ( BCG ) Superficial Bladder Cancer</brief_title>
	<detailed_description>The study randomize control study , design test efficacy safety new treatment modality prevention tumor recurrence superficial bladder cancer . Patients must tumors surgically resect prior study enrollment , undergo series test prove bladder free tumor . Eligible patient randomly assign one 2 treatment arm : 1 . A combination bladder wall heat local chemotherapy ( Synergo ) 2 . Bacillus Calmette-Guérin ( BCG ) Patients treat first year study , follow total 2 year . The follow include visual evaluation patient 's bladder cystoscopy , cytological examination urine ( look malignant cell ) additional exam . The patient ' general welfare monitor study . The aim study compare efficacy safety novel treatment ( Synergo ) well-known BCG</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>Superficial TCC : Any G3 T1 and/or CIS Multifocal ( &gt; 1 ) Ta lesion Multiple recurrence ( &gt; 2 ) Ta lesion last 24 month Complete tumor eradication must confirm WHO performance status 02 ( Appendix V ) Life expectancy 24 month Patients willing sign inform consent Bladder tumor TCC Coexistence another primary malignant tumor BCC skin TCC bladder involve urethra upper urinary tract Previous history TCC stage T2 high Clinical presence previous history regional spreading distant metastases Intravesical MMC treatment last 12 month Previous intravesical BCG therapy ( Any intravesical BCG therapy last 24 month , More 6 BCG intravesical instillation last 48 month . Previous pelvic radiotherapy systemic chemotherapy Partial cystectomy Diverticle bladder large 1cm diameter Residual urine &gt; 100cc measure uroflowmetry Bladder volume &lt; 150cc measure ultrasound Urinary incontinence ( one wet pad day ) Urethral stricture impede 20F catheterization Urethral bleeding persistent hematuria Active intractable uncontrollable UTI Active tuberculosis BCG infection Patients experience BCG life threaten sepsis Known allergy MMC BCG Known impair immune response , positive HIV serology , patient receive systemic steroid immunosuppressive therapy Hematological disorder ; leukocytes &lt; 3500 , platelets &lt; 100,000 Kidney liver function disorder ( 1.5 time upper normal limit ) Pregnant lactate woman Patients follow properly unable collaborate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Superficial urothelial cell carcinoma bladder</keyword>
	<keyword>NMIBC</keyword>
	<keyword>Non Muscle Invasive Bladder Cancer</keyword>
	<keyword>Hyperthermia</keyword>
	<keyword>Bladder instillation</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>RITE</keyword>
	<keyword>SHTC</keyword>
	<keyword>Intravesical</keyword>
</DOC>